Jim Pearce

Jim Pearce is the Chief Investment Strategist of Personal Finance, our flagship publication, and manages two trading services, PF Pro and Mayhem Trader. He began his career as a stockbroker in 1983 and over the years has managed client investment portfolios for major banks, brokerage firms, and investment advisors. Jim earned a BA from The College of William & Mary and the CFP designation from the College of Financial Planning.

Analyst Articles

As reported by Reuters this afternoon, shares of STI Next Wave portfolio holding Lattice Semiconductor (LSCC) jumped nearly 20% today after Tsinghua Unigroup, a China-based investment company, revealed that it has purchased a 6% stake in the company. That’s good news for LSCC, but bad news for STI Investments… Read More

As reported by Reuters this afternoon, shares of STI Next Wave portfolio holding Lattice Semiconductor (LSCC) jumped nearly 20% today after Tsinghua Unigroup, a China-based investment company, revealed that it has purchased a 6% stake in the company. That’s good news for LSCC, but bad news for STI Investments… Read More

Its no secret that embattled Yahoo (YHOO) CEO Marissa Mayer is under the gun to prove to shareholders that she should remain in her leadership position with the company. However, in this case its not only the CEO that is under the microscope, but the company’s entire board of directors… Read More

Its no secret that embattled Yahoo (YHOO) CEO Marissa Mayer is under the gun to prove to shareholders that she should remain in her leadership position with the company. However, in this case its not only the CEO that is under the microscope, but the company’s entire board of directors… Read More

Only three weeks ago we noted that the exoskeleton industry had made a number of significant advancements recently (“A Step in the Right Direction“). Since then one of our three exoskeleton stocks, Ekso Bionics (EKSO), got another big boost when it announced earlier this week that it received FDA… Read More

Only three weeks ago we noted that the exoskeleton industry had made a number of significant advancements recently (“A Step in the Right Direction“). Since then one of our three exoskeleton stocks, Ekso Bionics (EKSO), got another big boost when it announced earlier this week that it received FDA… Read More